Updated Analysis of Phase I Trial of Asciminib, a First-in-Class STAMP Inhibitor, in Patients With Previously Treated BCR-ABL1 T315I–Mutated CML

Source: 2020 American Society of Hematology Virtual Annual Meeting*
Download Slideset
December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
Twice-daily asciminib was associated with a major molecular response rate of 46.9% in pretreated patients with T315I-mutated CML, including those previously treated with ponatinib.
Format: Microsoft PowerPoint (.ppt)
File Size: 431 KB
Released: December 16, 2020

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Epizyme Inc.
GlaxoSmithKline
Incyte Corporation
Janssen Biotech, Inc.
Karyopharm Therapeutics Inc.
Novartis
PharmaEssentia Corp.
Seagen
Takeda Oncology

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings